CD163 and in situ carcinoma: The serum sCD163 levels increased significantly in the CIS/RRMS‐treated group from 1.336 to 1.706 mg/L (P = 0.04) and the levels of the corresponding sCD163 ratio decreased from 0.068 to 0.054 (P = 0.026).